Cadila Healthcare has informed that it has enclosed a copy of press release dated July 21, 2021 titled ‘European Medicines Agency grants Orphan Drug Designation to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC)’. Bring this news to the notice of the members of the exchange and the investors’ at large.
The above information is a part of company’s filings submitted to BSE.